Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pulse Biosciences

This Little-Known Biotech Stock Just Hit a New 5-Year High

Pulse Biosciences (PLSE) just hit a new 5-year high and has strong technical momentum. Shares are up more than 100% over the past 52 weeks. Revenue is projected to surge 652.38% this year and 236.71% next. Analyst sentiment is mixed, with ratings from “Strong Buy” to “Strong Sell,” reflecting its...

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Wednesday's Intraday Session

Pulse Biosciences's Return On Capital Employed Insights

Pulse Biosciences (NASDAQ:PLSE) brought in sales totaling $444.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 12.05%, resulting in a loss of $17.27 million.

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Pulse Biosciences: Q1 Earnings Insights

Pulse Biosciences (NASDAQ:PLSE) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Looking Into Pulse Biosciences's Return On Capital Employed

Looking Into Pulse Biosciences's Return On Capital Employed

Pulse Biosciences (NASDAQ:PLSE) brought in sales totaling $844.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.94%, resulting in a loss of $15.42 million.

Earnings Outlook For Pulse Biosciences

Earnings Outlook For Pulse Biosciences

Pulse Biosciences (NASDAQ:PLSE) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Pulse Biosciences will report an earnings per share (EPS) of $-0.51.

1

Organisations

Berkshire Hathaway

Western Digital

Micron Technology

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play